Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Published byBeverley Butler Modified over 5 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Clin. Oncol. doi: /nrclinonc"— Presentation transcript:

1 Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.204
Figure 4 Current post-surgery treatment strategies for major glioma entities classified according to the 2016 WHO Classification of Tumours of the Central Nervous System Figure 4 | Current post-surgery treatment strategies for major glioma entities classified according to the 2016 WHO Classification of Tumours of the Central Nervous System22. a | Standard post-surgery treatments of IDH-mutant adult gliomas. b | Standard post-surgery treatments of IDH-wild-type adult gliomas. c | Standard post-surgery treatments of common paediatric glioma entities. Dashed arrows indicate different treatment options depending on clinical risk factors in patients with WHO grade II gliomas. PCV, procarbazine, CCNU (lomustine), and vincristine; RT, radiotherapy; SEGA, subependymal giant-cell astrocytoma; TMZ, temozolomide; TMZ/RT→TMZ, radiotherapy with concomitant and maintainance temozolomide. *Diffuse astrocytoma, IDH-wild-type (WHO grade II) and anaplastic astrocytoma, IDH-wild-type (WHO grade III) are provisional entities according to the 2016 WHO classification. Reifenberger, G. et al. (2016) Advances in the molecular genetics of gliomas — implications for classification and therapy Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Nat. Rev. Clin. Oncol. doi: /nrclinonc"

Similar presentations

Figure 4 Progression-free survival, according to treatment group

Figure 4 Progression-free survival, according to treatment group
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
IDH1 mutant glioma cells are sensitive to TMZ

IDH1 mutant glioma cells are sensitive to TMZ
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Histopathology of low-grade glioma

Figure 1 Histopathology of low-grade glioma
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 3 Risk-adapted and response-adapted

Figure 3 Risk-adapted and response-adapted
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 3 Molecular subgroups of glioblastoma,

Figure 3 Molecular subgroups of glioblastoma,
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Similar presentations

Ads by Google